Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05304364




Registration number
NCT05304364
Ethics application status
Date submitted
7/03/2022
Date registered
31/03/2022
Date last updated
21/02/2023

Titles & IDs
Public title
Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)
Scientific title
Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching From Oral Naltrexone HCL to DLP-160 (Naltrexone Implant) to Intramuscular Vivitrol®
Secondary ID [1] 0 0
DLP-160-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Opiod Use Disorder 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Combination Product - Combination Product: Naltrexone

Experimental: DLP-160 alpha-10 - One time single Naltrexone Implant for a duration of 123 days


Combination Product: Combination Product: Naltrexone
Naltrexone Implant
Intervention code [1] 0 0
Combination Product
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
DLP-160 Adverse Events
Timepoint [1] 0 0
Day 1 to Day 120
Primary outcome [2] 0 0
DLP-160 Local Tolerance
Timepoint [2] 0 0
Day 1 to Day 120
Primary outcome [3] 0 0
Tolerability of DLP-160 Implantation and Removal Procedures
Timepoint [3] 0 0
Day 1 to Day 120
Secondary outcome [1] 0 0
Oral Pharmacokinetic (PK) Profile
Timepoint [1] 0 0
24 hours
Secondary outcome [2] 0 0
Implant Pharmacokinetic (PK) Profile
Timepoint [2] 0 0
4 months
Secondary outcome [3] 0 0
IM Naltrexone PK Profile
Timepoint [3] 0 0
1 month
Secondary outcome [4] 0 0
Evaluate the Drug Output of the DLP-160 Implant
Timepoint [4] 0 0
4 months

Eligibility
Key inclusion criteria
1. Must have given written informed consent before any study-related activities are
carried out and must be able to understand the full nature and purpose of the trial,
including possible risks and adverse effects.

2. Adult males and females, 18 to 50 years of age (inclusive) at the time of screening.

3. Body Mass Index (BMI) greater than or equal to 18.0 and lesser than or equal to 30.0
kg/m2, with a body weight (to 1 decimal place) greater than or equal to 50 kg.

4. Medically healthy without clinically significant abnormalities (in the opinion of the
Investigator) at the screening visit and prior to administration of the first study
dose on study Day -6, including:

1. Physical examination without any clinically significant findings.

2. Systolic blood pressure in the range of 90 to 160 mmHg (inclusive) and diastolic
blood pressure in the range of 50 to 95 mmHg (inclusive) after 5 minutes in
supine (or semi-supine) position.

3. Heart rate (HR) in the range of 45 to 100 bpm (inclusive) after 5 minutes rest in
a supine (or semi-supine) position.

4. Body temperature (tympanic or oral) in the range 35.5°C to 37.7°C (inclusive).

5. No clinically significant findings in serum chemistry, haematology, coagulation,
and urinalysis tests.

6. Triplicate 12-lead ECG (taken after the volunteer has been supine (or
semi-supine) for at least 5 minutes) with a QT interval corrected using the
Fridericia method (QTcF) lesser than or equal to 450 msec for males and lesser
than or equal to 470 msec for females and no clinically significant
abnormalities.

Note: Minor abnormalities or deviations outside the normal ranges for any of the
clinical testing (laboratory tests, ECG, vital signs) may be repeated at the
discretion of the Investigator. Such abnormalities or deviations are acceptable for
participation in the study if judged to be not clinically significant by the
Investigator. Platelet count and coagulation measures must be within normal limits.

5. Female volunteers must:

1. Be of nonchildbearing potential i.e., be surgically sterilised (hysterectomy,
bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before
screening) or be postmenopausal, where menopause is defined as 12 months of
amenorrhea in the absence of other biological causes (females under the age of 55
years must have a documented serum follicle stimulating hormone (FSH) level
greater than 40mIU/mL to confirm menopause).

2. If of childbearing potential (defined as any female who has experienced menarche
and who has not undergone surgical sterilisation and is not postmenopausal), the
participant:

- Must have a negative serum test at the screening visit and a negative urine
pregnancy test within 24 hours prior to the start of study drug.

- Must not be breastfeeding, lactating or planning pregnancy during the study
period.

- Must agree not to attempt to become pregnant.

- If not exclusively in same-sex relationships, must agree to use adequate
contraception (which is defined as use of a condom by the male partner
combined with use of a highly effective method of contraception by the
female partner); after signing consent, during the study, and at least 35
days after the last dose of study drug;

- Must agree to not donate ova for at least 35 days after the last dose of
study drug.

6. Male participants, if not surgically sterilised, must agree to:

1. Not donate sperm after signing consent, during the study, and at least 95 days
after the last dose of study drug.

2. If engaging in sexual intercourse with a female partner who could become
pregnant, use a condom in addition to having the female partner use a highly
effective contraceptive method.

3. Have suitable venous access for blood sampling.

7. Be willing and able to comply with all study assessments and adhere to the protocol
schedule and restrictions.
Minimum age
18 Years
Maximum age
50 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological
disease, including any acute illness or major surgery within the past 3 months
determined by the PI to be clinically significant (participants with resolved
childhood asthma may be included in the study).

2. Current infection that requires systemically absorbed antibiotic, antifungal,
antiparasitic or antiviral medications.

3. Liver function test results elevated more than 1.5-fold above the upper limit of
normal (ULN) for gamma glutamyl transferase (GGT), bilirubin (total, conjugated and
unconjugated), alkaline phosphatase (ALP), aspartate aminotransferase (AST) or alanine
aminotransferase (ALT). Volunteers with ALP and/or ALT/AST above the limits specified
may be included, at the discretion of the Investigator, if the levels are
unaccompanied by clinical signs and are determined to be normal variants.

4. Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2),
hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the
screening visit.

5. Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions
known to interfere with the absorption, distribution, metabolism, or excretion of
drugs (prior gall bladder and/or appendix removal is not exclusionary if deemed
appropriate by the Investigator).

6. Estimated creatinine clearance (CrCl) less than 80 mL/min using the Cockcroft-Gault
formula or serum creatinine more than 1.5-fold above the ULN.

7. Presence of clinically significant skin disorders (such as, but not limited to, skin
cancer, psoriasis, eczema, or atopic dermatitis), evidence of recent sunburn, scar
tissue, tattoo, open sore, body piercing or branding at the intended placement site
that would interfere with the placement procedure or interfere with implant site
assessments as determined by the Investigator.

8. History of abnormal scar formation or family history of keloid formation.

9. Known hypersensitivity to titanium, implant materials or the procedure of implant
placement.

10. Previously defined hypersensitivity to Naltrexone.

11. Known hypersensitivity or allergy to lidocaine or any local anaesthetic agent of the
amide type (local anaesthetic used during placement and removal procedures).

12. History of substance abuse, in the opinion of the Investigator.

13. History of alcohol abuse (defined as more than an average of 14 standard drinks per
week or regular consumption of more than 4 standard drinks on any one day; where 1
standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9%
Alc./Vol], 100 mL wine [12% Alc./Vol], 30 mL spirit [40% Alc./Vol]).

14. Positive drugs of abuse or alcohol breath test results at the screening visit or prior
to the first study drug administration on Day -6 and at check-in on Day -2.

15. Use of any prescription or over-the-counter medication (including herbal products, and
hormone supplements) within 10 days or 5 half-lives of the medication (whichever is
longer) prior to the first study drug administration - exceptions include
contraceptives for females, occasional use of paracetamol (doses of 500 mg up to every
6 hours or 2 g per day maximum for no more than 3 consecutive days), ibuprofen (doses
of 400 mg up to every 6 hours or 1.2 g per day maximum for no more than 3 consecutive
days), topical ointments, and vitamins or dietary supplements.

16. Demonstrated clinically significant (required intervention, e.g., emergency room
visit, epinephrine administration) allergic reactions (e.g., food, drug, or atopic
reactions, asthmatic episodes) which, in the opinion of the Investigator, would
interfere with the volunteer's ability to participate in the trial.

17. For women of childbearing potential, a positive serum pregnancy test at the screening
visit or a positive urine pregnancy test (with confirmatory serum pregnancy test)
prior to the first study drug administration on Day -6 and at check-in on Day -2.

18. Females who are breastfeeding or planning to breast feed at any time during the study.

19. Donation of blood or plasma within 30 days prior to first study drug administration,
or loss of whole blood of more than 500 mL within 30 days prior to first study drug
administration, or receipt of a blood transfusion within 1 year of first study drug
administration.

20. Intolerance of direct venepuncture.

21. Treatment with an investigational drug (or device) in another clinical trial within 30
days or 5 half-lives of the other investigational drug (whichever is longer) prior to
the first administration of study drug in this trial.

22. Anticipated surgical procedure or current painful condition that is likely to require
opioid analgesia during the trial.

23. Any other condition or prior therapy that in the opinion of the Investigator would
make the volunteer unsuitable for this study, including inability to cooperate fully
with the requirements of the study protocol or likelihood of noncompliance with any
study requirements.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/03/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/11/2022
Sample size
Target
Accrual to date
Final
10
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Delpor, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is an Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and
Pharmacokinetics of Switching from Oral Naltrexone HCL to DLP-160 (Naltrexone implant) to
Intramuscular Vivitrol®
Trial website
https://clinicaltrials.gov/ct2/show/NCT05304364
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Alex Choo, MD
Address 0 0
CMAX
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries